On December 20, 2023, Investor’s Business Daily reported that argenx ‘s “stock crashed early Wednesday after its treatment for an autoimmune disease that causes skin blisters flopped in a Phase 3 study.” Based on this news, shares of the Company’s stock were down by more than 25% in intraday trading on the same day.